Metallotexaphyrin-based neurodegenerative disease therapies - PharmacyclicsAlternative Names: Amyotrophic lateral sclerosis metallotexaphyrin therapy
Latest Information Update: 21 Mar 2007
At a glance
- Originator Pharmacyclics
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 12 Sep 2003 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)